Haifa, Israel: Advanced cancer patients who use cannabis during chemotherapy treatment show greater improvement in disease-related symptoms as compared to controls, according to clinical trial data published in the journal Anti-Cancer Drugs.
Israeli researchers assessed outcomes associated with patients’ use of cannabis over a three-month period versus matched controls. Those who used cannabis adjunctively showed superior improvement as compared to abstainers in various domains, including greater reductions in fatigue, insomnia, and appetite loss. Cases also showed improved executive function as compared to controls. Other cognitive domains showed no differences between the two groups.
"These findings are significant, given the increasing use of cannabis among this population," authors concluded. "Larger and more representative studies should be carried out to further investigate this field."
For more information, contact Paul Armentano, NORML Deputy Director, at: firstname.lastname@example.org. Full text of the study, "Cannabis-related cognitive impairment: A prospective evaluation of possible influences on patients with cancer during chemotherapy treatment as a pilot study," appears in Anti-Cancer Agents.